Proteome Medicine Sweden -ProMS

Purpose and goal

We aim to build a translational environment to integrate proteomics into precision medicine. Recent breakthroughs in methods enable comprehensive proteome data to be developed for clinical decision support. We will harness our proteomics technology platforms to demonstrate proof of concept in cancer proteomics, connecting research, healthcare and industry. Our vision is to improve diagnostics and therapy decisions by adding a new layer of data, that of proteomics, to precision medicine.

Expected effects and result

The integration of proteomics data into precision medicine diagnostics is expected to improve individualized cancer therapy selection. The unique molecular phenotype view based on proteomics enables deeper understanding of treatment response and contributes to making Sweden attractive as a clinical trial nation. ProMS will form a coordinated clinical proteomics environment that will foster national and international collaboration, improving its role in future EU precision medicine initiatives.

Planned approach and implementation

To build an innovative clinical proteomics environment for precision medicine we will perform proof of concept studies in cancer proteomics through observational clinical trials and prospective clinical analysis, developing national standards for sample collection, preparation, DIA MS analysis, and targeted MS analysis. We will establish data sharing, generate a common data analysis pipeline, and integrate proteomics data with other modalities using the Molecular Tumor Board Portal.